Sarepta won't stick around for pivotal gene therapy readout

14 January 2022

gene_genetic_test_biotech_biomarker_lab_research_2022_big

A licensing deal between Paris, France-based gene therapist Lysogene (Euronext: LYS) and Sarepta Therapeutics (Nasdaq: SRPT) has been terminated.

Lysogene is working on a gene therapy platform with the goal of targeting central nervous system (CNS) diseases.

The deal with USA-based Sarepta relates to LYS-SAF302, a Phase II/III asset for the treatment of the rare disease mucopolysaccharidosis Type IIIA (MPS IIIA).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK